Consistent with these findings, the current study confirmed that the semaglutide-intensified treatment group exhibited reduced fasting plasma glucose, fasting insulin, total cholesterol, triglyceride, and LDL-C levels compared with baseline
9 (12):e23113 22
Reduces body fat, facilitating weight loss
Also see if there are any supplements you should avoid if you are taking estrogen replacement
Regarding pancreatitis, other data have argued that, Switching between GLP-1 agonists may increase the risk of adverse effects, especially if dose titration protocols are not followed. Noteworthy: Other studies have found that semaglutide and tirzepatide may actually decrease the risk of recurrent acute pancreatitis. Above all, if you suspect you may be developing pancreatitis, consult with your doctor right away, who will likely advise you to stop taking the medication
Magnes Res, 1997